Wockhardt gets USFDA’s approval for Prostate cancer drug

01 Mar 2019 Evaluate

Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for an ANDA for 250 mg tablet of Abiraterone acetate, which is used to treat Prostate Cancer. Wockhardt's Abiraterone acetate tablet is a generic version of Zytiga, marketed in USA and other countries by Johnson & Johnson.

Wockhardt will be launching this product in the United States, in a short period of time. With its nationwide distribution network and its excellent relationship with all major trade, retail and institutional customers, Wockhardt is already a significant player in the US pharmaceutical market. The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1445.75 -12.80 (-0.88%)
02-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1878.00
Dr. Reddys Lab 1373.70
Cipla 1537.55
Lupin 2396.30
Zydus Lifesciences 990.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.